Understanding Brain Cancer

How Long Will I Live With Brain Cancer?

Last updated and reviewed on June 16, 2026.

After a brain cancer diagnosis, one of the most pressing questions on a person's mind and on the minds of their family is usually some version of "What does this mean for how long I have?" It is one of the hardest questions in medicine, and the honest answer is that no doctor can predict exactly what will happen for any one person. What doctors can share are statistical numbers based on large groups of patients, and those numbers, while imperfect, can help guide realistic conversations about what to expect and how to plan.

What is also true is that brain cancer is not one disease. It covers a wide range of tumor types, from slow-growing meningiomas that many people live with for decades, to glioblastoma, which remains one of the most challenging cancers in medicine. The numbers look very different depending on which type of brain cancer a person has.

How Common Is Brain Cancer?

Brain tumors, both cancerous and non-cancerous, are diagnosed in about 94,000 Americans each year, according to the Central Brain Tumor Registry of the United States (CBTRUS). Of those, approximately 25,400 are malignant (cancerous) primary brain tumors. Brain cancer accounts for roughly 1.4 percent of all new cancer diagnoses.

The most common malignant brain tumor in adults is glioblastoma (GBM), which makes up about 14 percent of all primary brain tumors and nearly half of all malignant gliomas. Despite being relatively rare in comparison to cancers like breast or colon cancer, brain cancer receives significant research attention because of its severity and the enormous impact it has on quality of life.

What Is the Survival Rate for Brain Cancer?

Because brain cancer encompasses so many different tumor types, it is not possible to give a single survival rate that applies to everyone. The numbers vary dramatically based on the specific tumor type, grade, and location, as well as individual factors like age and overall health.

The following survival data is based on information from the SEER (Surveillance, Epidemiology, and End Results) database maintained by the National Cancer Institute. These are 5-year relative survival rates — meaning the percentage of people who are still alive 5 years after diagnosis compared to people of the same age without the disease.

What Factors Affect Prognosis?

Several things influence how a person with brain cancer is likely to do over time. Understanding these can help you have a more informed conversation with your care team:

• Tumor type and grade matter more than almost anything else. A glioblastoma (Grade 4) carries a very different prognosis than a Grade 2 oligodendroglioma. Grade describes how abnormal the cells look and how fast they grow. Higher-grade tumors grow faster and are harder to treat.
• Molecular markers have transformed brain cancer prognosis in recent years. Certain genetic features of the tumor, like IDH mutation status, MGMT promoter methylation, 1p/19q codeletion, and TERT promoter mutation, are now routinely tested and have become as important as grade in predicting outcomes and guiding treatment. For example, glioblastomas with a methylated MGMT promoter respond better to temozolomide chemotherapy and tend to have longer survival than those without it.
• Age at diagnosis matters significantly. Younger patients generally do better than older patients with the same tumor type. This may be because younger brains have more resilience or because younger patients can tolerate more aggressive treatment.
• The extent of surgical resection, how much of the tumor the surgeon was able to safely remove, correlates with outcomes. A gross total resection (removing virtually all visible tumor) is generally associated with better outcomes than a partial removal.
• Location of the tumor affects both outcomes and treatment options. A tumor in an area of the brain that is safe to operate on (called non-eloquent cortex) is easier to remove than a tumor near critical areas controlling speech or movement (called eloquent cortex).
• Overall health and functional status influence how well a person tolerates treatment and recovers from surgery.

Is Brain Cancer Curable?

The answer depends on the type of brain cancer. Some types are highly curable. Most benign meningiomas, for example, can be completely cured with surgery. Many low-grade gliomas can be controlled for a decade or more with treatment, and some patients do very well for many years. Certain medulloblastomas in children are curable with combined treatment.

For high-grade tumors like glioblastoma, a cure in the traditional sense is currently rare. Most people with glioblastoma experience recurrence despite treatment. However, the word rare is not the same as impossible; some patients with glioblastoma do achieve long-term survival beyond five years, and researchers are working hard to understand why and to develop treatments that could extend those results to more patients. Clinical trials are actively testing new immunotherapies, targeted therapies, and other approaches that may improve outcomes in the coming years.

Sources:

1. Ostrom QT, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015–2019. Neuro-Oncology. 2022. https://academic.oup.com/neuro-oncology/article/24/Supplement_5/v1/6742201

2. National Cancer Institute SEER Database. Cancer Stat Facts: Brain and Other Nervous System. https://seer.cancer.gov/statfacts/html/brain.html

3. Stupp R, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New England Journal of Medicine. 2005;352(10):987–996. https://www.nejm.org/doi/full/10.1056/NEJMoa043330

4. Louis DN, et al. The 2021 WHO Classification of Tumors of the Central Nervous System. Neuro-Oncology. 2021;23(8):1231–1251. https://pubmed.ncbi.nlm.nih.gov/34185076/

5. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2024. CA: A Cancer Journal for Clinicians. 2024;74(1):12–49. https://pubmed.ncbi.nlm.nih.gov/38230766/

6. Mellinghoff IK, et al. Glioblastoma and Other Primary Brain Malignancies in Adults. JAMA. 2023. PMC11445779. https://pmc.ncbi.nlm.nih.gov/articles/PMC11445779/

7. American Cancer Society. Survival Rates for Selected Adult Brain and Spinal Cord Tumors. https://www.cancer.org/cancer/types/brain-spinal-cord-tumors-adults/detection-diagnosis-staging/survival-rates.html

8. Weller M, et al. EANO Guidelines on the Diagnosis and Treatment of Diffuse Gliomas of Adulthood. Nature Reviews Clinical Oncology. 2021. PubMed: 33603203. https://pubmed.ncbi.nlm.nih.gov/33293629/